BeOne presents phase 3 data showing BRUKINSA benefits in elderly CLL patients
Tweet Send to a Friend
BeOne Medicines Ltd. (NASDAQ: ONC) presented phase 3 clinical trial data at the 2026 European Hematology Association Congress showing sustained ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
